FOR IMMEDIATE RELEASE
Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640
WASHINGTON, D.C. – The National Women’s Health Network (the Network) is profoundly disappointed with the U.S. Food and Drug Administration’s (FDA) decision to approve flibanserin, a proposed treatment for female sexual dysfunction, despite inadequate proof of effectiveness and questionable assurances of the drug’s safety. The FDA’s recommendation for ...

FOR IMMEDIATE RELEASE
Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788
The National Women’s Health Network (“the Network”) urges the FDA to oppose the approval of Sprout Pharmaceutical’s female sexual dysfunction drug flibanserin. The Network has come to this position after careful consideration of newly disclosed research and thorough evaluation of the drug’s extensive and ...

FOR IMMEDIATE RELEASE
Contact: Coco Jervis 202.407.0788
Advocates from the National Women’s Health Network are out in force this week at the FDA and on the Hill urging FDA officials to approve of a proposed Generic Drug Labeling Rule. This rule would give women access to better and more accurate information about the risks and benefits of ...

Share Your Story

Since You Asked

Having an independent voice whose sole constituent is women is important. The Network makes sure that women’s stories, issues, and health concerns are addressed both at a grassroots level and through federal policy. It’s trustworthy, it’s unapologetic, and industry doesn’t silence the NWHN.